Organization
IRCCS Humanitas Research Hospital, Rozzano, Italy
10 abstracts
1 poster
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.Org: University Medical Center Mainz, University Grenoble Alpes, CHU Grenoble Alpes, Institute for Advanced Biosciences, Kindai University Faculty of Medicine, Osaka-Sayama, Japan,
Abstract
Enrichment of glioblastoma tumor microenvironment in a GZMK+ T cell population.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Laboratory of Translational Immunology, Department of Biomedical Sciences, Humanitas University,
Abstract
Correlation of comprehensive molecular mapping of pancreatic ductal adenocarcinoma with XPO1 mRNA expression levels to potential clinical targets.Org: Caris Life Sciences, Irving, TX, IRCCS Humanitas Research Hospital, Rozzano, Italy, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Sarah Cannon Research Institute UK Limited, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,
Abstract
Circulating tumor DNA of classical Hodgkin lymphoma.Org: Institute of Oncology Research, Aou Federico II, AO S.Croce e Carle, Clinical and Experimental Onco Hematology Unit, Medical University of Gdansk,
Abstract
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.Org: Memorial Sloan Kettering Cancer Center, Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Department of Thoracic Oncology, Peking University Cancer Hospital, IRCCS Humanitas Research Hospital, Rozzano, Italy,
Abstract
A MONOCENTRIC COHORT ANALYSIS OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS WITHOUT MYOSITIS-SPECIFIC AND ASSOCIATED AUTOANTIBODIESOrg: Humanitas University, IRCCS Humanitas Research Hospital, Rozzano, Italy,